Under which circumstances these cross-reactive CD4+ T cells are primed remains unclear but their frequent HLA-DRB1*1501 restriction would explain additive MS risk due to HLA-DRB1*1501 expression and EBV infection. The gene discussed is HLA-DRB1; the disease is myeloid sarcoma.